Title:
ＥＧＦＲ－標的製剤に対する感受性予測用の新規なバイオマーカー及びその用途
Document Type and Number:
Japanese Patent JP7369672
Kind Code:
B2
Abstract:
The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d' Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent. According to the present disclosure, since an effect of predicting the susceptibility to the EGFR-targeted agent is excellent in a colon cancer, the present disclosure may be useful in the treatment of the colon cancer.
Inventors:
Kim Tae Won
Jin Dong Hoon
Hong Seung Woo
Moon Jae Hee
Shin Jae Sik
Kim Seung Mi
Lee Dae Hee
Lee Eun Yoon
Lee Seul
Hong Yong San
Jin Dong Hoon
Hong Seung Woo
Moon Jae Hee
Shin Jae Sik
Kim Seung Mi
Lee Dae Hee
Lee Eun Yoon
Lee Seul
Hong Yong San
Application Number:
JP2020114949A
Publication Date:
October 26, 2023
Filing Date:
July 02, 2020
Export Citation:
Assignee:
WELLMARKERBIO CO., LTD.
International Classes:
C12N15/09; C07K16/30; C12N15/57; G01N33/574; G01N33/577
Domestic Patent References:
| JP6779858B1 |
Other References:
Cancer Lett.,2013年,Vol. 340,p. 43-50
Attorney, Agent or Firm:
Sykes Patent Attorney Corporation